Drug Trial Radar · NCT05131477
Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study
Last checked: Nov 19, 2026Latest source record: Jul 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
390
Actual
Start
Dec 13, 2021
Primary completion
Apr 26, 2023
Study completion Feb 21, 2024
Sponsor
- Lead sponsor
- Kymab LimitedIndustry
- Sponsor type
- Industry
- Collaborators
- Sanofi
- First posted
- Nov 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 5-arm study to assess the effect of Anti-OX40L Monoclonal Antibody (KY1005) in adult participants with moderate to severe atopic dermatitis. The estimated duration is 28 days for screening and then up to approximately day 477 (last dose no later than day 337+140 days safety follow-up) for all patients unless enrolled into the Long-Term Extension (LTE) protocol (NCT05492578) at either Day 169 depending on responder status or no later than Day 365 due to loss of clinical response.
Conditions
- Eczema
- Atopic Dermatitis
Interventions
AmlitelimabDrug
Pharmaceutical form: Injection solution Route of administration: Subcutaneous
PlaceboDrug
Pharmaceutical form: Injection solution Route of administration: Subcutaneous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Change in EASI (Eczema Area and Severity Index) From Baseline to Week 16 (Part 1)Time frame: Baseline to week 16
Locations
103 sites in 12 countries. Site status is shown where the registry gives one.
Investigative Site Number: 1018
Fremont, California
Investigative site #1022
Sacramento, California
Investigative Site Number: 1006
Boca Raton, Florida
Investigative Site Number: 1001
Clearwater, Florida
Investigative Site Number: 1019
Coral Gables, Florida
Investigative Site Number: 1007
Miami, Florida
Investigative Site Number: 1013
Tampa, Florida
Investigative Site Number: 1004
Savannah, Georgia
Investigative Site Number: 1010
Clarksville, Indiana
Investigative Site Number: 1015
Indianapolis, Indiana
Investigative Site Number: 1021
Louisville, Kentucky
Investigative Site Number: 1011
Towson, Maryland
Investigative Site Number: 1014
Beverly, Massachusetts
Investigative Site Number: 1012
Troy, Michigan
Investigative Site Number: 1005
Tulsa, Oklahoma
Investigative Site Number: 1017
Portland, Oregon
Investigative Site Number: 1009
Portland, Oregon
Investigative Site Number: 1003
Anderson, South Carolina
Investigative Site Number: 1008
Murfreesboro, Tennessee
Investigative site #1023
Mansfield, Texas
Investigative Site Number 3002
Carlton, Australia
Investigative Site Number: 3003
East Melbourne, Australia
Investigational Site Number: 3001
Parkville, Australia
Investigative Site Number: 2004
Pleven, Bulgaria
Investigative Site Number: 2005
Sofia, Bulgaria
Investigative Site Number: 2006
Sofia, Bulgaria
Investigative Site Number: 2003
Sofia, Bulgaria
Investigative Site Number: 2002
Sofia, Bulgaria
Investigative Site Number: 2001
Stara Zagora, Bulgaria
Investigative Site Number: 1106
Markham, Ontario, Canada
Investigative site #1108
Niagara Falls, Ontario, Canada
Investigative Site Number: 1103
Ottawa, Ontario, Canada
Investigative Site Number: 1107
Waterloo, Ontario, Canada
Investigative Site Number: 1101
Windsor, Ontario, Canada
Investigative Site Number: 2106
Kutná Hora, Czechia
Investigative Site Number: 2104
Ostrava, Czechia
Investigative Site Number: 2105
Nový Jicín, Moravian-Silesian Region, Czechia
Investigative Site Number: 2102
Prague, Praha, Hlavní Mesto, Czechia
Investigative Site Number: 2103
Prague, Praha, Hlavní Mesto, Czechia
Investigative Site Number: 2108
Brno, South Moravian, Czechia
Showing 40 of 103 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.